Download PDF
Semin Respir Crit Care Med 2004; 25(5): 595-607
DOI: 10.1055/s-2004-836150
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Biologic Immunomodulatory Therapies in the Vasculitic Diseases

Carol A. Langford1
  • 1Center for Vasculitis Care and Research, Department of Rheumatic and Immunologic Diseases, The Cleveland Clinic Foundation, Cleveland, Ohio
Further Information

Publication History

Publication Date:
09 November 2004 (online)

    Permissions and Reprints

The expanding range of biologic agents capable of modulating the immune response has opened up a new realm for therapeutic exploration in the vasculitic diseases. Partnered with increasing knowledge regarding the mechanisms of vascular inflammation, these agents have raised the question as to whether it may be possible to treat systemic vasculitis syndromes by selectively targeting pathways involved in disease pathogenesis. The action of these agents to directly modulate specific immunologic components offers the potential not only to impact disease activity but also to reduce the risk of morbidity that can result from currently available treatment options. The study of biologic therapies in the vasculitides must, however, be approached with caution because unanticipated effects on disease activity and disease-specific toxicities can occur. The only biologic agent that has currently been shown to have therapeutic efficacy in a systemic vasculitis syndrome is interferon-α in the treatment of hepatitis C-associated cryoglobulinemic vasculitis. The use of biologic agents to treat other vasculitides remains investigational. Methodical evaluation of biologic agents prior to their use in general clinical practice is essential to understand their safety and efficacy. Rigorous, standardized investigations may also provide important insights into pathogenesis of the vasculitic diseases.

KEYWORDS

Vasculitis - monoclonal - recombinant - biologic - treatment

REFERENCES

  • 1 Criscione L G, St Clair E W. Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases.  Curr Opin Rheumatol. 2002;  14 204-211
    CrossrefPubMedGoogle Scholar
  • 2 Patel D D. B cell-ablative therapy for the treatment of autoimmune diseases.  Arthritis Rheum. 2002;  46 1984-1985
    CrossrefPubMedGoogle Scholar
  • 3 Fisher Jr C J, Agosti J M, Opal S M et al.. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.  N Engl J Med. 1996;  334 1697-1702
    CrossrefPubMedGoogle Scholar
  • 4 Robinson W H, Genovese M C, Moreland L W. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?.  Arthritis Rheum. 2001;  44 1977-1983
    CrossrefPubMedGoogle Scholar
  • 5 TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study . The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.  Neurology. 1999;  53 457-465
    PubMedGoogle Scholar
  • 6 Sicotte N L, Voskuhl R R. Onset of multiple sclerosis associated with anti-TNF therapy.  Neurology. 2001;  57 1885-1888
    PubMedGoogle Scholar
  • 7 van Oosten B W, Barkhof F, Truyen L et al.. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.  Neurology. 1996;  47 1531-1534
    CrossrefPubMedGoogle Scholar
  • 8 Sneller M C. Granuloma formation, implications for the pathogenesis of vasculitis.  Cleve Clin J Med. 2002;  69(suppl 2) SII40-SII43
    PubMedGoogle Scholar
  • 9 Ludviksson B R, Sneller M C, Chua K S et al.. Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10.  J Immunol. 1998;  160 3602-3609
    PubMedGoogle Scholar
  • 10 Csernok E, Trabandt A, Müller A et al.. Cytokine profiles in Wegener's granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation.  Arthritis Rheum. 1999;  42 742-750
    CrossrefPubMedGoogle Scholar
  • 11 Stone J H, Uhlfelder M L, Hellmann D B et al.. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety.  Arthritis Rheum. 2001;  44 1149-1154
    CrossrefPubMedGoogle Scholar
  • 12 Lamprecht P, Voswinkel J, Lilienthal T et al.. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis.  Rheumatology (Oxford). 2002;  41 1303-1307
    CrossrefPubMedGoogle Scholar
  • 13 Booth A D, Jefferson H J, Ayliffe W, Andrews P A, Jayne D R. Safety and efficacy of TNFalpha blockade in relapsing vasculitis.  Ann Rheum Dis. 2002;  61 559
    CrossrefPubMedGoogle Scholar
  • 14 Bartolucci P, Ramanoelina J, Cohen P et al.. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients.  Rheumatology (Oxford). 2002;  41 1126-1132
    CrossrefPubMedGoogle Scholar
  • 15 Russell K A, Specks U. Are antineutrophil cytoplasmic antibodies pathogenic? Experimental approaches to understand the antineutrophil cytoplasmic antibody phenomenon.  Rheum Dis Clin North Am. 2001;  27 815-832
    CrossrefPubMedGoogle Scholar
  • 16 Preston G A, Yang J J, Xiao H, Falk R J. Understanding the pathogenesis of ANCA: where are we today?.  Cleve Clin J Med. 2002;  69(suppl 2) SII51-SII54
    PubMedGoogle Scholar
  • 17 Xiao H, Heeringa P, Hu P et al.. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice.  J Clin Invest. 2002;  110 955-963
    CrossrefPubMedGoogle Scholar
  • 18 Specks U, Fervenza F C, McDonald T J, Hogan M C. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy.  Arthritis Rheum. 2001;  44 2836-2840
    CrossrefPubMedGoogle Scholar
  • 19 Lockwood C M, Thiru S, Isaacs J D, Hale G, Waldmann H. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy.  Lancet. 1993;  341 1620-1622
    CrossrefPubMedGoogle Scholar
  • 20 Lockwood C M, Thiru S, Stewart S et al.. Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies.  QJM. 1996;  89 903-912
    PubMedGoogle Scholar
  • 21 Jayne D RW. CAMPATH-1H (anti-CD-52) for refractory vasculitis: retrospective Cambridge experience 1989-1999.  Cleve Clin J Med. 2002;  69(suppl 2) SII-129
    PubMedGoogle Scholar
  • 22 Mathieson P W, Cobbold S P, Hale G et al.. Monoclonal-antibody therapy in systemic vasculitis.  N Engl J Med. 1990;  323 250-254
    PubMedGoogle Scholar
  • 23 Churg J, Strauss L. Allergic granulomatosis, allergic angiitis and periarteritis nodosa.  Am J Pathol. 1951;  27 277-301
    PubMedGoogle Scholar
  • 24 Hellmich B, Ehlers S, Csernok E, Gross W L. Update on the pathogenesis of Churg-Strauss syndrome.  Clin Exp Rheumatol. 2003;  21(6 suppl 32) S69-S77
    PubMedGoogle Scholar
  • 25 Kiene M, Csernok E, Muller A et al.. Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg-Strauss syndrome.  Arthritis Rheum. 2001;  44 469-473
    CrossrefPubMedGoogle Scholar
  • 26 Bockenstedt P L, Santinga J T, Bolling S F. Alpha-interferon treatment for idiopathic hypereosinophilic syndrome.  Am J Hematol. 1994;  45 248-251
    PubMedGoogle Scholar
  • 27 Mohr C, Schutte B, Hildebrand A, Luger T A, Kolde G. Eosinophilic pustular folliculitis: successful treatment with interferon-alpha.  Dermatology. 1995;  191 257-259
    PubMedGoogle Scholar
  • 28 Husak R, Goerdt S, Orfanos C E. Interferon alfa treatment of a patient with eosinophilic cellulitis and HIV infection.  N Engl J Med. 1997;  337 641-642
    CrossrefPubMedGoogle Scholar
  • 29 Aldebert D, Lamkhioued B, Desaint C et al.. Eosinophils express a functional receptor for interferon alpha: inhibitory role of interferon alpha on the release of mediators.  Blood. 1996;  87 2354-2360
    PubMedGoogle Scholar
  • 30 Tatsis E, Schnabel A, Gross W L. Interferon-alpha treatment of four patients with the Churg-Strauss syndrome.  Ann Intern Med. 1998;  129 370-374
    CrossrefPubMedGoogle Scholar
  • 31 Lesens O, Hansmann Y, Nerson J et al.. Severe Churg-Strauss syndrome with mediastinal lymphadenopathy treated with interferon therapy.  Eur J Intern Med. 2002;  13 458
    PubMedGoogle Scholar
  • 32 Kroegel C, Mock B, Reissig A. Interferons and their application in lung diseases.  Chest. 2003;  124 2406-2407
    CrossrefPubMedGoogle Scholar
  • 33 Termeer C C, Simon J C, Schopf E. Low-dose interferon alfa-2b for the treatment of Churg-Strauss syndrome with prominent skin involvement.  Arch Dermatol. 2001;  137 136-138
    PubMedGoogle Scholar
  • 34 Hellmich B, Gross W L. Recent progress in the pharmacotherapy of Churg-Strauss syndrome.  Expert Opin Pharmacother. 2004;  5 25-35
    CrossrefPubMedGoogle Scholar
  • 35 Arbach O, Gross W L, Gause A. Treatment of refractory Churg-Strauss-Syndrome (CSS) by TNF-alpha blockade.  Immunobiology. 2002;  206 496-501
    CrossrefPubMedGoogle Scholar
  • 36 Weyand C M, Goronzy J J. Medium- and large-vessel vasculitis.  N Engl J Med. 2003;  349 160-169
    CrossrefPubMedGoogle Scholar
  • 37 Weyand C M, Goronzy J J. Giant-cell arteritis and polymyalgia rheumatica.  Ann Intern Med. 2003;  139 505-515
    CrossrefPubMedGoogle Scholar
  • 38 Brack A, Geisler A, Martinez-Taboada V M et al.. Giant cell vasculitis is a T cell-dependent disease.  Mol Med. 1997;  3 530-543
    PubMedGoogle Scholar
  • 39 Cantini F, Niccoli L, Salvarani C, Padula A, Olivieri I. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases.  Arthritis Rheum. 2001;  44 2933-2935
    CrossrefPubMedGoogle Scholar
  • 40 Andonopoulos A P, Meimaris N, Daoussis D, Bounas A, Giannopoulos G. Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis.  Ann Rheum Dis. 2003;  62 1116
    CrossrefPubMedGoogle Scholar
  • 41 Airo P, Antonioli C M, Vianelli M, Toniati P. Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs.  Rheumatology (Oxford). 2002;  41 347-349
    CrossrefPubMedGoogle Scholar
  • 42 Tan A L, Holdsworth J, Pease C, Emery P, McGonagle D. Successful treatment of resistant giant cell arteritis with etanercept.  Ann Rheum Dis. 2003;  62 373-374
    CrossrefPubMedGoogle Scholar
  • 43 Agnello V, Romain P L. Mixed cryoglobulinemia secondary to hepatitis C virus infection.  Rheum Dis Clin North Am. 1996;  22 1-21
    CrossrefPubMedGoogle Scholar
  • 44 Sneller M C, Fauci A S. Pathogenesis of vasculitis syndromes.  Med Clin North Am. 1997;  81 221-242
    PubMedGoogle Scholar
  • 45 Dispenzieri A, Gorevic P D. Cryoglobulinemia.  Hematol Oncol Clin North Am. 1999;  13 1315-1349
    PubMedGoogle Scholar
  • 46 Lamprecht P, Gause A, Gross W L. Cryoglobulinemic vasculitis.  Arthritis Rheum. 1999;  42 2507-2516
    PubMedGoogle Scholar
  • 47 Vassilopoulos D, Calabrese L H. Hepatitis C virus infection and vasculitis: implications of antiviral and immunosuppressive therapies.  Arthritis Rheum. 2002;  46 585-597
    CrossrefPubMedGoogle Scholar
  • 48 Bonomo L, Casato M, Afeltra A, Caccavo D. Treatment of idiopathic mixed cryoglobulinemia with alpha interferon.  Am J Med. 1987;  83 726-730
    CrossrefPubMedGoogle Scholar
  • 49 Casato M, Lagana B, Antonelli G, Dianzani F, Bonomo L. Long-term results of therapy with interferon-alpha for type II essential mixed cryoglobulinemia.  Blood. 1991;  78 3142-3147
    PubMedGoogle Scholar
  • 50 Migliaresi S, Tirri G. Interferon in the treatment of mixed cryoglobulinemia.  Clin Exp Rheumatol. 1995;  13(suppl 13) S175-S180
    PubMedGoogle Scholar
  • 51 Cresta P, Musset L, Cacoub P et al.. Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus.  Gut. 1999;  45 122-128
    PubMedGoogle Scholar
  • 52 Mazzaro C, Lacchin T, Moretti M et al.. Effects of two different alpha-interferon regimens on clinical and virological findings in mixed cryoglobulinemia.  Clin Exp Rheumatol. 1995;  13(suppl 13) S181-S185
    PubMedGoogle Scholar
  • 53 Casato M, Agnello V, Pucillo L P et al.. Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection.  Blood. 1997;  90 3865-3873
    PubMedGoogle Scholar
  • 54 Pellicano R, Marietti G, Leone N et al.. Mixed cryoglobulinaemia associated with hepatitis C virus infection: a predictor factor for treatment with interferon?.  J Gastroenterol Hepatol. 1999;  14 1108-1111
    CrossrefPubMedGoogle Scholar
  • 55 Cohen P, Nguyen Q T, Deny P et al.. Treatment of mixed cryoglobulinemia with recombinant interferon alpha and adjuvant therapies: a prospective study on 20 patients.  Ann Med Interne (Paris). 1996;  147 81-86
    PubMedGoogle Scholar
  • 56 Polzien F, Schott P, Mihm S, Ramadori G, Hartmann H. Interferon-alpha treatment of hepatitis C virus-associated mixed cryoglobulinemia.  J Hepatol. 1997;  27 63-71
    CrossrefPubMedGoogle Scholar
  • 57 Calleja J L, Albillos A, Moreno-Otero R et al.. Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia.  Aliment Pharmacol Ther. 1999;  13 1179-1186
    CrossrefPubMedGoogle Scholar
  • 58 Misiani R, Bellavita P, Fenili D et al.. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus.  N Engl J Med. 1994;  330 751-756
    CrossrefPubMedGoogle Scholar
  • 59 Ferri C, Marzo E, Longombardo G et al.. Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial.  Blood. 1993;  81 1132-1136
    PubMedGoogle Scholar
  • 60 Dammacco F, Sansonno D, Han J H et al.. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study.  Blood. 1994;  84 3336-3343
    PubMedGoogle Scholar
  • 61 Poynard T, Marcellin P, Lee S S et al.. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT).  Lancet. 1998;  352 1426-1432
    CrossrefPubMedGoogle Scholar
  • 62 McHutchison J G, Gordon S C, Schiff E R et al.. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.  N Engl J Med. 1998;  339 1485-1492
    CrossrefPubMedGoogle Scholar
  • 63 Cacoub P, Lidove O, Maisonobe T et al.. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.  Arthritis Rheum. 2002;  46 3317-3326
    CrossrefPubMedGoogle Scholar
  • 64 Zuckerman E, Keren D, Slobodin G et al.. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha.  J Rheumatol. 2000;  27 2172-2178
    PubMedGoogle Scholar
  • 65 Manns M P, McHutchison J G, Gordon S C et al.. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.  Lancet. 2001;  358 958-965
    CrossrefPubMedGoogle Scholar
  • 66 Hadziyannis S J, Sette H, Morgan T R et al.. Peginterferon-alpha2a and ribavirin combination therapy inchronic hepatitis C: a randomized study of treatment duration and ribavirin dose.  Ann Intern Med. 2004;  140 346-355
    CrossrefPubMedGoogle Scholar
  • 67 Fried M W, Shiffman M L, Reddy K R et al.. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.  N Engl J Med. 2002;  347 975-982
    CrossrefPubMedGoogle Scholar
  • 68 Sansonno D, De Re V, Lauletta G et al.. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20.  Blood. 2003;  101 3818-3826
    CrossrefPubMedGoogle Scholar
  • 69 Zaja F, De Vita S, Mazzaro C et al.. Efficacy and safety of rituximab in type II mixed cryoglobulinemia.  Blood. 2003;  101 3827-3834
    CrossrefPubMedGoogle Scholar
  • 70 Arzoo K, Sadeghi S, Liebman H A. Treatment of refractory antibody-mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab).  Ann Rheum Dis. 2002;  61 922-924
    CrossrefPubMedGoogle Scholar
  • 71 Lamprecht P, Lerin-Lozano C, Merz H et al.. Rituximab induces remission in refractory HCV-associated cryoglobulinaemic vasculitis.  Ann Rheum Dis. 2003;  62 1230-1233
    CrossrefPubMedGoogle Scholar
  • 72 Gocke D J, Hsu K, Morgan C et al.. Association between polyarteritis and Australia antigen.  Lancet. 1970;  2 1149-1153
    PubMedGoogle Scholar
  • 73 Trepo C, Thivolet J. Hepatitis associated antigen and periarteritis nodosa (PAN).  Vox Sang. 1970;  19 410-411
    PubMedGoogle Scholar
  • 74 Guillevin L, Lhote F, Sauvaget F et al.. Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges.  Ann Rheum Dis. 1994;  53 334-337
    PubMedGoogle Scholar
  • 75 Nakamura H, Shimizu T, Ohshiro S et al.. An adult patient with acute hepatitis type B which was protracted and complicated by polyarteritis nodosa: a case report.  Hepatol Res. 2002;  24 439-444
    PubMedGoogle Scholar
  • 76 Duzova A, Bakkaloglu A, Yuce A, Ozen S, Kocak N. Successful treatment of polyarteritis nodosa with interferon alpha in a nine-month-old girl.  Eur J Pediatr. 2001;  160 519-520
    PubMedGoogle Scholar
  • 77 Deleaval P, Stadler P, Descombes E et al.. Life-threatening complications of hepatitis B virus-related polyarteritis nodosa developing despite interferon-alpha2b therapy: successful treatment with a combination of interferon, lamivudine, plasma exchanges and steroids.  Clin Rheumatol. 2001;  20 290-292
    CrossrefPubMedGoogle Scholar
  • 78 Erhardt A, Sagir A, Guillevin L, Neuen-Jacob E, Haussinger D. Successful treatment of hepatitis B virus-associated polyarteritis nodosa with a combination of prednisolone, alpha-interferon, and lamivudine.  J Hepatol. 2000;  33 677-683
    CrossrefPubMedGoogle Scholar
  • 79 Wicki J, Olivieri J, Pizzolato G et al.. Successful treatment of polyarteritis nodosa related to hepatitis B virus with a combination of lamivudine and interferon alpha.  Rheumatology (Oxford). 1999;  38 183-185
    CrossrefPubMedGoogle Scholar
  • 80 Molloy P J, Friedlander L, Van Thiel D H, Kania R J. Combined interferon, famciclovir and GM-CSF treatment of HBV infection in an individual with periarteritis nodosa.  Hepatogastroenterology. 1999;  46 2529-2531
    PubMedGoogle Scholar
  • 81 Avsar E, Savas B, Tozun N, Ulusoy N B, Kalayci C. Successful treatment of polyarteritis nodosa related to hepatitis B virus with interferon alpha as first-line therapy.  J Hepatol. 1998;  28 525-526
    PubMedGoogle Scholar
  • 82 Kruger M, Boker K H, Zeidler H, Manns M P. Treatment of hepatitis B-related polyarteritis nodosa with famciclovir and interferon alfa-2b.  J Hepatol. 1997;  26 935-939
    CrossrefPubMedGoogle Scholar
  • 83 Sonntag K C, Schwarz-Eywill M, Hunstein W. Is interferon alpha a therapy for hepatitis B-associated polyarteritis nodosa?.  Br J Rheumatol. 1995;  34 486-487
    PubMedGoogle Scholar
  • 84 Simsek H, Telatar H. Successful treatment of hepatitis B virus-associated polyarteritis nodosa by interferon alpha alone.  J Clin Gastroenterol. 1995;  20 263-265
    PubMedGoogle Scholar
  • 85 Darras-Joly C, Lortholary O, Cohen P, Brauner M, Guillevin L. Regressing microaneurysms in 5 cases of hepatitis B virus-related polyarteritis nodosa.  J Rheumatol. 1995;  22 876-880
    PubMedGoogle Scholar
  • 86 Mouthon L, Deblois P, Sauvaget F et al.. Hepatitis B virus-related polyarteritis nodosa and membranous nephropathy.  Am J Nephrol. 1995;  15 266-269
    PubMedGoogle Scholar
  • 87 Frassanito M A, Dammacco R, Cafforio P, Dammacco F. Th1 polarization of the immune response in Behçet's disease: a putative pathogenetic role of interleukin-12.  Arthritis Rheum. 1999;  42 1967-1974
    CrossrefPubMedGoogle Scholar
  • 88 Turan B, Gallati H, Erdi H et al.. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bechcet's disease; soluble TNFR-75 as a biological marker of disease activity.  J Rheumatol. 1997;  24 128-132
    PubMedGoogle Scholar
  • 89 Sfikakis P P. Behçet's disease: a new target for anti-tumour necrosis factor treatment.  Ann Rheum Dis. 2002;  61(suppl 2) ii51-ii53
    PubMedGoogle Scholar
  • 90 Sfikakis P P, Theodossiadis P G, Katsiari C G, Kaklamanis P, Markomichelakis N N. Effect of infliximab on sight-threatening panuveitis in Behçet's disease.  Lancet. 2001;  358 295-296
    CrossrefPubMedGoogle Scholar
  • 91 Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J, Schlincker A, Martin-Mola E. Effect of infliximab on threatening panuveitis in Behçet's disease.  Lancet. 2001;  358 1644
    PubMedGoogle Scholar
  • 92 Triolo G, Vadala M, Accardo-Palumbo A et al.. Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behçet's disease.  Ann Rheum Dis. 2002;  61 560-561
    CrossrefPubMedGoogle Scholar
  • 93 Morris D S, Gavin M P, Sturrock R D. The effect of anti-tumour necrosis factor alpha (infliximab) on sight-threatening uveitis in a patient with Behçet's disease.  Adv Exp Med Biol. 2003;  528 557-559
    PubMedGoogle Scholar
  • 94 Goossens P H, Verburg R J, Breedveld F C. Remission of Behçet's syndrome with tumour necrosis factor alpha blocking therapy.  Ann Rheum Dis. 2001;  60 637
    CrossrefPubMedGoogle Scholar
  • 95 Robertson L P, Hickling P. Treatment of recalcitrant orogenital ulceration of Behçet's syndrome with infliximab.  Rheumatology (Oxford). 2001;  40 473-474
    CrossrefPubMedGoogle Scholar
  • 96 Saulsbury F T, Mann J A. Treatment with infliximab for a child with Behçet's disease.  Arthritis Rheum. 2003;  49 599-600
    CrossrefPubMedGoogle Scholar
  • 97 Gulli S, Arrigo C, Bocchino L et al.. Remission of Behçet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report.  BMC Musculoskelet Disord. 2003;  4 19
    CrossrefPubMedGoogle Scholar
  • 98 Behrens F, Zollner T, Moeller B et al.. Antitumor necrosis factor monoclonal antibody therapy in a woman with severe Adamantiades-Behçet's disease.  Adv Exp Med Biol. 2003;  528 561-562
    PubMedGoogle Scholar
  • 99 Estrach C, Mpofu S, Moots R J. Behçet's syndrome: response to infliximab after failure of etanercept.  Rheumatology (Oxford). 2002;  41 1213-1214
    CrossrefPubMedGoogle Scholar
  • 100 Rozenbaum M, Rosner I, Portnoy E. Remission of Behçet's syndrome with TNFalpha blocking treatment.  Ann Rheum Dis. 2002;  61 283-284
    CrossrefPubMedGoogle Scholar
  • 101 Mussack T, Landauer N, Ladurner R et al.. Successful treatment of cervical esophageal perforation in Behçet's disease with drainage operation and infliximab.  Am J Gastroenterol. 2003;  98 703-704
    CrossrefPubMedGoogle Scholar
  • 102 Kram M T, May L D, Goodman S, Molinas S. Behçet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case.  Dis Colon Rectum. 2003;  46 118-121
    CrossrefPubMedGoogle Scholar
  • 103 Hassard P V, Binder S W, Nelson V, Vasiliauskas E A. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report.  Gastroenterology. 2001;  120 995-999
    PubMedGoogle Scholar
  • 104 Travis S P, Czajkowski M, McGovern D P, Watson R G, Bell A L. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody.  Gut. 2001;  49 725-728
    CrossrefPubMedGoogle Scholar
  • 105 Licata G, Pinto A, Tuttolomondo A et al.. Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behçet's syndrome.  Ann Rheum Dis. 2003;  62 280-281
    CrossrefPubMedGoogle Scholar
  • 106 Alpsoy E, Kodelja V, Goerdt S, Orfanos C E, Zouboulis Ch C. Serum of patients with Behçet's disease induces classical (pro-inflammatory) activation of human macrophages in vitro.  Dermatology. 2003;  206 225-232
    CrossrefPubMedGoogle Scholar
  • 107 Kotter I, Gunaydin I, Treusch M et al.. The use of interferon-alpha in Behçet's disease: review of the literature and possible mechanisms of action.  Adv Exp Med Biol. 2003;  528 503-509
    PubMedGoogle Scholar
  • 108 Hamzaoui K, Ayed K, Slim A, Hamza M, Touraine J. Natural killer cell activity, interferon-gamma and antibodies to herpes viruses in patients with Behçet's disease.  Clin Exp Immunol. 1990;  79 28-34
    PubMedGoogle Scholar
  • 109 Krause L, Turnbull J R, Torun N et al.. Interferon alfa-2a in the treatment of ocular Adamantiades-Behçet's disease.  Adv Exp Med Biol. 2003;  528 511-519
    PubMedGoogle Scholar
  • 110 Krause L, Hoffmann F, Zouboulis C C, Foerster M H. Vitrectomy and trabeculectomy combined with interferon alpha treatment in Adamantiades-Behçet's disease: a case report.  Graefes Arch Clin Exp Ophthalmol. 2003;  241 871-874
    CrossrefPubMedGoogle Scholar
  • 111 Deuter C M, Kotter I, Gunaydin I, Zierhut M, Stubiger N. Behçet's disease: visual acuity after 5 years in patients with alpha-interferon treatment.  Adv Exp Med Biol. 2003;  528 525-528
    PubMedGoogle Scholar
  • 112 Strohal R, Tschachler E, Breyer S et al.. Reactivation of Behçet's disease in the course of multicentric HHV8-positive Castleman's disease: long-term complete remission by a combined chemo/radiation and interferon-alpha therapy regimen.  Br J Haematol. 1998;  103 788-790
    CrossrefPubMedGoogle Scholar
  • 113 O'Duffy J D, Calamia K, Cohen S et al.. Interferon-alpha treatment of Behçet's disease.  J Rheumatol. 1998;  25 1938-1944
    PubMedGoogle Scholar
  • 114 Kotter I, Eckstein A K, Stubiger N, Zierhut M. Treatment of ocular symptoms of Behçet's disease with interferon alpha 2a: a pilot study.  Br J Ophthalmol. 1998;  82 488-494
    PubMedGoogle Scholar
  • 115 Hamuryudan V, Ozyazgan Y, Fresko Y et al.. Interferon alfa combined with azathioprine for the uveitis of Behçet's disease: an open study.  Isr Med Assoc J. 2002;  4(11 Suppl) 928-930
    PubMedGoogle Scholar
  • 116 Calguneri M, Ozturk M A, Ertenli I et al.. Effects of interferon alpha treatment on the clinical course of refractory Behçet's disease: an open study.  Ann Rheum Dis. 2003;  62 492-493
    CrossrefPubMedGoogle Scholar
  • 117 Nichols J C, Ince A, Akduman L, Mann E S. Interferon-alpha 2a treatment of neuro-Behçet disease.  J Neuroophthalmol. 2001;  21 109-111
    PubMedGoogle Scholar
  • 118 Wechsler B, Bodaghi B, Huong D L et al.. Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease.  Ocul Immunol Inflamm. 2000;  8 293-301
    PubMedGoogle Scholar
  • 119 Stuebiger N, Koetter I, Zierhut M. Complete regression of retinal neovascularization after therapy with interferon alfa in Behçet's disease.  Br J Ophthalmol. 2000;  84 1437-1438
    PubMedGoogle Scholar
  • 120 Boyvat A, Sisman-Solak C, Gurler A. Long-term effects of interferon alpha 2A treatment in Behçet's disease.  Dermatology. 2000;  201 40-43
    CrossrefPubMedGoogle Scholar
  • 121 Kotter I, Aepinus C, Graepler F et al.. HHV8-associated Kaposi's sarcoma during triple immunosuppressive treatment with cyclosporin A, azathioprine, and prednisolone for ocular Behçet's disease and complete remission of both disorders with interferon alpha.  Ann Rheum Dis. 2001;  60 83-86
    CrossrefPubMedGoogle Scholar
  • 122 Aoki T, Tanaka T, Akifuji Y et al.. Beneficial effects of interferon-alpha in a case with Behçet's disease.  Intern Med. 2000;  39 667-669
    PubMedGoogle Scholar
  • 123 Kosar A, Haznedaroglu S, Karaaslan Y et al.. Effects of interferon-alpha2a treatment on serum levels of tumor necrosis factor-alpha, tumor necrosis factor-alpha2 receptor, interleukin-2, interleukin-2 receptor, and E-selectin in Behçet's disease.  Rheumatol Int. 1999;  19 11-14
    CrossrefPubMedGoogle Scholar
  • 124 Georgiou S, Monastirli A, Pasmatzi E et al.. Efficacy and safety of systemic recombinant interferon-alpha in Behçet's disease.  J Intern Med. 1998;  243 367-372
    CrossrefPubMedGoogle Scholar
  • 125 Pivetti-Pezzi P, Accorinti M, Pirraglia M P, Priori R, Valesini G. Interferon alpha for ocular Behçet's disease.  Acta Ophthalmol Scand. 1997;  75 720-722
    PubMedGoogle Scholar
  • 126 Kotter I, Durk H, Eckstein A et al.. Erosive arthritis and posterior uveitis in Behçet's disease: treatment with interferon alpha and interferon gamma.  Clin Exp Rheumatol. 1996;  14 313-315
    PubMedGoogle Scholar
  • 127 Azizlerli G, Sarica R, Kose A et al.. Interferon alfa-2a in the treatment of Behçet's disease.  Dermatology. 1996;  192 239-241
    PubMedGoogle Scholar
  • 128 Munke H, Stockmann F, Ramadori G. Possible association between Behçet's syndrome and chronic hepatitis C virus infection.  N Engl J Med. 1995;  332 400-401
    CrossrefPubMedGoogle Scholar
  • 129 Alpsoy E, Yilmaz E, Basaran E. Interferon therapy for Behçet's disease.  J Am Acad Dermatol. 1994;  31 617-619
    PubMedGoogle Scholar
  • 130 Feron E J, Rothova A, van Hagen P M, Baarsma G S, Suttorp-Schulten M S. Interferon-alpha 2b for refractory ocular Behçet's disease.  Lancet. 1994;  343 1428
    PubMedGoogle Scholar
  • 131 Hamuryudan V, Moral F, Yurdakul S et al.. Systemic interferon alpha 2b treatment in Behçet's syndrome.  J Rheumatol. 1994;  21 1098-1100
    PubMedGoogle Scholar
  • 132 Durand J M, Kaplanski G, Telle H, Soubeyrand J, Paulo F. Beneficial effects of interferon-alpha 2b in Behçet's disease.  Arthritis Rheum. 1993;  36 1025-1026
    PubMedGoogle Scholar
  • 133 Tsambaos D, Eichelberg D, Goos M. Behçet's syndrome: treatment with recombinant leukocyte alpha-interferon.  Arch Dermatol Res. 1986;  278 335-336
    CrossrefPubMedGoogle Scholar
  • 134 Grimbacher B, Wenger B, Deibert P et al.. Loss of vision and diarrhoea.  Lancet. 1997;  350 1818
    CrossrefPubMedGoogle Scholar
  • 135 Durusoy C, Alpsoy E, Yilmaz E. Pityriasis rosea in a patient with Behçet's disease treated with interferon alpha 2A.  J Dermatol. 1999;  26 225-228
    PubMedGoogle Scholar
  • 136 Zouboulis C C, Orfanos C E. Treatment of Adamantiades-Behçet disease with systemic interferon alfa.  Arch Dermatol. 1998;  134 1010-1016
    CrossrefPubMedGoogle Scholar
  • 137 Alpsoy E, Durusoy C, Yilmaz E et al.. Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study.  Arch Dermatol. 2002;  138 467-471
    CrossrefPubMedGoogle Scholar
  • 138 Kotter I, Zierhut M, Eckstein A K et al.. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight-threatening posterior or panuveitis.  Br J Ophthalmol. 2003;  87 423-431
    CrossrefPubMedGoogle Scholar
  • 139 Lockwood C M, Hale G, Waldman H, Jayne D R. Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H.  Rheumatology (Oxford). 2003;  42 1539-1544
    CrossrefPubMedGoogle Scholar

Carol A LangfordM.D. M.H.S. 

Center for Vasculitis Care and Research, Department of Rheumatic and Immunologic Diseases, The Cleveland Clinic Foundation

9500 Euclid Ave., A50

Cleveland, OH 44195

Email: langfoc@ccf.org

      >